ATE494010T1 - Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung - Google Patents

Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung

Info

Publication number
ATE494010T1
ATE494010T1 AT03716207T AT03716207T ATE494010T1 AT E494010 T1 ATE494010 T1 AT E494010T1 AT 03716207 T AT03716207 T AT 03716207T AT 03716207 T AT03716207 T AT 03716207T AT E494010 T1 ATE494010 T1 AT E494010T1
Authority
AT
Austria
Prior art keywords
materials
production
methods
therapeutic delivery
delivery compositions
Prior art date
Application number
AT03716207T
Other languages
English (en)
Inventor
Elijah Bolotin
Original Assignee
Pharmain Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmain Corp filed Critical Pharmain Corp
Application granted granted Critical
Publication of ATE494010T1 publication Critical patent/ATE494010T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
AT03716207T 2002-02-27 2003-02-27 Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung ATE494010T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36035002P 2002-02-27 2002-02-27
PCT/US2003/005937 WO2003072143A1 (en) 2002-02-27 2003-02-27 Compositions for delivery of therapeutics and other materials, and methods of making and using the same

Publications (1)

Publication Number Publication Date
ATE494010T1 true ATE494010T1 (de) 2011-01-15

Family

ID=27766225

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03716207T ATE494010T1 (de) 2002-02-27 2003-02-27 Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung

Country Status (8)

Country Link
US (2) US7138105B2 (de)
EP (1) EP1478406B1 (de)
JP (1) JP2005524657A (de)
AT (1) ATE494010T1 (de)
AU (1) AU2003219922B2 (de)
CA (1) CA2476589C (de)
DE (1) DE60335608D1 (de)
WO (1) WO2003072143A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
EP1486216A4 (de) * 2002-02-26 2006-08-23 Amato Pharm Prod Ltd Verfahren zur verkapselung eines metallkomplexes mit liposomen
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
AU2003219922B2 (en) * 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20100069293A1 (en) * 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7629049B2 (en) * 2002-10-18 2009-12-08 Medasorb, Inc. Hemocompatible polymer systems and related devices
US20060235114A1 (en) * 2003-07-28 2006-10-19 Teijin Limited Temperature-responsive hydrogel
CN1829743B (zh) * 2003-07-30 2010-06-30 安特易斯有限公司 生物医用的复合基质
MXPA06000803A (es) * 2003-09-10 2006-08-23 Cristalia Prod Quimicos Farm Composicion farmaceutica estable del compuesto de fluoroeter para uso anestesico, metodo para estabilizar un compuesto de fluoroeter, uso del agente estabilizador para evitar la degradacion de un compuesto de fluoroeter.
WO2005080489A1 (fr) * 2004-02-23 2005-09-01 Caiteng Zhang Solution de chelate(s) metal/polymere et leurs utilisations
HUE025656T2 (en) * 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
BRPI0404983A (pt) * 2004-09-03 2006-05-02 Nanocore Biotecnologia Ltda composições imunogênicas
CN101137398B (zh) * 2005-01-05 2012-07-04 得克萨斯大学体系董事会 用于双重显像和放射化疗的缀合物：组合物、生产和应用
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20090291508A1 (en) * 2008-05-20 2009-11-26 Rapid Pathogen Screening Inc. Nanoparticles in diagnostic tests
KR20070110402A (ko) * 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
WO2007028607A2 (de) * 2005-09-09 2007-03-15 Aesculap Ag & Co. Kg Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
US20090324587A1 (en) 2005-12-01 2009-12-31 Neal Clifford Goodwin Cancer Therapies and Pharmaceutical Compositions Used Therein
KR101529318B1 (ko) * 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US9604196B2 (en) 2006-11-20 2017-03-28 Cytosorbent, Inc. Size-selective hemocompatible polymer system
JP2010510248A (ja) * 2006-11-21 2010-04-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分をターゲティング部分と組み合わせて使用する金属酸化還元酵素阻害剤
US20090246155A1 (en) * 2006-12-05 2009-10-01 Landec Corporation Compositions and methods for personal care
US20100004124A1 (en) * 2006-12-05 2010-01-07 David Taft Systems and methods for delivery of materials for agriculture and aquaculture
US8399007B2 (en) * 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US20100210792A1 (en) * 2006-12-05 2010-08-19 David Taft Drug delivery
US20090263346A1 (en) * 2006-12-05 2009-10-22 David Taft Systems and methods for delivery of drugs
WO2008128058A1 (en) * 2007-04-13 2008-10-23 The Trustees Of The University Of Pennsylvania New gallium bisaminothiolate complexes for myocardial imaging
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US8252302B2 (en) * 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US9095568B2 (en) * 2007-09-26 2015-08-04 Mark Berninger Therapeutic and vaccine polyelectrolyte nanoparticle compositions
US8114883B2 (en) * 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
EP3685837A1 (de) * 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Formulierungen mit verzögerter freisetzung unter verwendung nichtwässriger träger
CA2773737C (en) 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
EP2343051B1 (de) 2010-01-05 2014-07-30 National Dong Hwa University Formulierung gegen Krebs
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012240131B2 (en) 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
US8785569B2 (en) * 2011-11-22 2014-07-22 Original Biomedicals Co., Ltd. Drug carrier with chelating complex micelles and the application thereof
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN107075555B (zh) 2014-09-24 2021-12-03 高露洁-棕榄公司 金属离子的生物利用度
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
CN105054074A (zh) * 2015-07-01 2015-11-18 浙江海洋学院 一种鱼糜酶解肽亚铁螯合物抗氧化微胶囊及其制备工艺
EP4019575B1 (de) 2015-10-09 2023-12-06 Le Dévédec, Frantz Vernetzte partikel
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11905377B2 (en) 2019-01-17 2024-02-20 Pendant Biosciences, Inc. Factors controlling drug release in cross-linked poly(valerolactone) based matrices
WO2020254540A1 (en) 2019-06-18 2020-12-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents
MX2022014143A (es) * 2020-05-12 2022-11-30 Basf Se Uso de polimero carboximetilado de lisinas como agente dispersante y composiciones que comprenden el mismo.
WO2025207519A1 (en) * 2024-03-23 2025-10-02 Texas Tech University System Biocompatible and biodegradable polymer nanodiscs as lipoprotein-mimicking nanocarriers with high stability and long circulation time for drug delivery

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5681543A (en) 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5776894A (en) 1988-12-05 1998-07-07 Novartis Ag Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors
US5554388A (en) 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
WO1993009176A2 (en) 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US5770563A (en) 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
AU682308C (en) 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
JPH08501097A (ja) 1992-09-04 1996-02-06 ザ ゼネラル ホスピタル コーポレーション 臨床診断及び治療用部分を含む生体適合性ポリマー
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5605672A (en) 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5763585A (en) 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
EP0804249A2 (de) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeres system zur freisetzung von genen
US5466467A (en) 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5929031A (en) 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5855610A (en) 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
EP0830381A4 (de) 1995-06-09 2000-11-22 William N Drohan Chitinhydrogele, herstellungsverfahren und anwendung
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
AU730969B2 (en) 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JPH10158195A (ja) * 1996-11-28 1998-06-16 Res Inst For Prod Dev 配位結合を利用した薬物−高分子複合体製剤の調製方法
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6153211A (en) 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
DE19740069A1 (de) * 1997-09-12 1999-03-18 Clariant Gmbh Mischungen von langkettigen Phosphorsäurealkylestern
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7056734B1 (en) 1998-08-10 2006-06-06 The United States Of America As Represented By The Department Of Health And Human Services, Nih Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
IL140892A0 (en) 1998-08-12 2002-02-10 Yissum Res Dev Co Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP2002534363A (ja) * 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
CA2328614C (en) 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
JP4647792B2 (ja) 1999-04-28 2011-03-09 イジュノシッヒ テクニッヒ ホッフシューラ チューリッヒ 分析用デバイスおよびセンシングデバイスにおけるポリイオン性コーティング
EP1223947A4 (de) * 1999-10-15 2004-12-08 Canji Inc Zielgerichtete vektoren
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1487836A (zh) 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU2001263230B2 (en) 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
US6338859B1 (en) 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
DK1301213T3 (en) 2000-07-21 2017-03-27 Revance Therapeutics Inc MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT
US20040092432A1 (en) 2000-08-24 2004-05-13 Thomas Jefferson University Peptide compositions with effects on cerebral health
US6521736B2 (en) 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
CA2395165C (en) 2000-10-20 2012-05-22 Mario Ehlers Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US20020132254A1 (en) * 2000-11-30 2002-09-19 Twu Jesse J. Molecular labeling and assay systems using poly (amino acid)-metal ion complexes as linkers
AU2002239384B2 (en) 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
JP2005506956A (ja) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
AU2002322403A1 (en) 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
HUP0600437A2 (en) 2001-10-01 2006-09-28 Lilly Co Eli Glucagon-like peptides (glp-1) and treatment of respiratory distress
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
IL161446A0 (en) 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
AU2003208945B2 (en) 2002-02-20 2008-05-01 Emisphere Technologies, Inc Method for administering GLP-1 molecules
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
AU2003219922B2 (en) 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
MXPA04012497A (es) 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
RU2005133427A (ru) 2003-03-31 2006-04-27 Алза Корпорейшн (Us) Безводные однофазные носители и препараты с использованием таких носителей
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
ES2375056T3 (es) 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
JP2007514752A (ja) 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
US20060074025A1 (en) 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
FR2867679B1 (fr) 2004-03-17 2008-08-22 Oreal Composition cosmetiques comprenant des polyamines modifiees et utilisations desdites compositions.
EP1737899B1 (de) 2004-04-20 2015-07-08 Dendritic Nanotechnologies, Inc. Dendritische polymere mit verbesserter amplifikation und innerer funktion
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
US7285529B2 (en) 2005-02-28 2007-10-23 Gene Tools, Llc Embedder compositions and methods for detecting and killing cells in acidic areas of tumors
US20090202497A1 (en) 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
WO2007030706A1 (en) 2005-09-08 2007-03-15 New England Medical Center Hospitals, Inc. Fragments of the glucagon-like peptide-i and uses thereof
HUE031341T2 (hu) 2005-10-25 2017-07-28 Starpharma Pty Ltd Ellenõrzött sztöchiometriájú makromolekuláris vegyületek
PL1965823T3 (pl) 2005-11-04 2017-08-31 Glaxosmithkline Llc Sposoby podawania środków hipoglikemicznych
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
WO2007082331A1 (en) 2006-01-20 2007-07-26 Starpharma Pty Limited Modified macromolecule
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same

Also Published As

Publication number Publication date
US7790140B2 (en) 2010-09-07
AU2003219922A1 (en) 2003-09-09
US7138105B2 (en) 2006-11-21
DE60335608D1 (de) 2011-02-17
EP1478406A1 (de) 2004-11-24
WO2003072143A1 (en) 2003-09-04
JP2005524657A (ja) 2005-08-18
AU2003219922B2 (en) 2009-09-10
US20060239924A1 (en) 2006-10-26
CA2476589A1 (en) 2003-09-04
US20030224974A1 (en) 2003-12-04
EP1478406A4 (de) 2006-01-11
EP1478406B1 (de) 2011-01-05
CA2476589C (en) 2014-02-25
WO2003072143A9 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
DE60335608D1 (de) Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
DE60021729D1 (de) Photosensibilisatoren enthaltende antimikrobielle zusammensetzung, gegenstände und verfahren zur verwendung
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
DE50015883D1 (de) Flächiges Implantat, Verfahren zu seiner Herstellung und Verwendung in der Chirurgie
WO2004006906A3 (en) Methods for the treatment of neoplasms
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
ATE549996T1 (de) Verfahren zur herstellung von chitosan- wundauflagen
WO2002041837A3 (en) Treatment of mucositis
DE60043229D1 (de) Zusammensetzung zur gefässbeschichtung
AU2003272654A1 (en) Polymer compositions containing bioactive agents and methods for their use
GB0307834D0 (en) Composition
DE69939475D1 (de) Blockpolymerzusammensetzung, verfahren zu dessen herstellung und druckempfindliche klebstoffzusammensetzung
SG150559A1 (en) Antineoplastic combinations of cci-779 and rituximab
MX2007003470A (es) Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa.
ATE520781T1 (de) Verfahren zur veränderung des gehalts von speicherstoffen in pflanzen
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
AU2003251787A1 (en) Polymerized and modified rapamycins and their use in coating medical prostheses
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE60225449D1 (de) Wildlederartiges kunstleder und verfahren zu dessen herstellung
DE60237659D1 (de) Kathodenmaterial zur Verwendung in Lithium-Sekundärbatterie, und Verfahren zu seiner Herstellung
DE69918984D1 (de) Stärkeabbau/pfropfpolymerisation : zusammensetzung, verfahren und verwendungen
ATA6302000A (de) Haftmittel für zahnprothesen und verfahren zu seiner herstellung
DE602004020874D1 (de) Zusammensetzungen enthaltend hohe konzentration von kontrastmittel zur embolisierung von blutgefassen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties